Research programme: toll-like receptor inhibitors - Dynavax Technologies

Drug Profile

Research programme: toll-like receptor inhibitors - Dynavax Technologies

Alternative Names: IRS-954

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dynavax Technologies
  • Developer Dynavax Technologies; GlaxoSmithKline
  • Class Oligonucleotides
  • Mechanism of Action Toll-like receptor 7 antagonists; Toll-like receptor 9 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA
  • 08 Mar 2016 Dynavax Technologies has patent protection for its TLR agonists and antagonists in USA (Dynavax Technology, Form 10-K, March 2016)
  • 28 Nov 2014 Dynavax Technologies regains full rights to all TLR 7/9 inhibitors for all indications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top